Ignite Creation Date:
2024-05-06 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 2:16 PM
Study NCT ID:
NCT05093725
Status:
UNKNOWN
Last Update Posted:
2021-10-26
First Post:
2021-10-13
Brief Title:
CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage
Status:
UNKNOWN
Status Verified Date:
2021-10
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Human mesenchymal stem cells MSCs due to their regenerative and immunomodulatory properties are widely used for the treatment of bone and cartilage damage cardiovascular gastrointestinal autoimmune neurodegenerative diseases and cancer It is shown that the use of MSCs in therapy is safe and can be effective In 2006 the International Society for Cellular Therapy ISCT proposed the minimal criteria to define human MSCs First MSCs must be plastic-adherent when maintained in the standard culture conditions Second MSCs must express CD105 CD73 and CD90 and lack expression of CD45 CD34 CD14 or CD11b CD79a or CD19 and HLA-DR surface molecules
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None